Alembic eyes $259M cancer market with tentative US nod for Binimetinib
Sole first applicant with Paragraph IV, Alembic qualifies for 180-day generic exclusivity on a melanoma and NSCLC drug. This is its largest single-product opportunity this year.
— 6 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- Alembic received tentative US approval for generic Binimetinib 45 mg tablets, a kinase inhibitor used in melanoma and NSCLC.
- The drug is a generic version of Array's Mektovi, with an estimated US market of $259M (₹2,150 cr).
- As the sole first applicant with a Paragraph IV certification, Alembic is eligible for 180 days of marketing exclusivity upon final approval.
Why this matters
At ~29% of Alembic's annual revenue, this is a materially large opportunity. The 180-day exclusivity window gives Alembic a rare moat against competition, potentially securing a meaningful revenue stream in oncology, a high-value therapeutic area.
What we're watching
- Timeline of final approval — once granted, the exclusivity clock starts.
- Whether any other filers challenge the Paragraph IV certification.
- Launch execution and pricing strategy for a drug with a $259M market.
The full read
Alembic Pharmaceuticals has locked in a tentative US approval for generic Binimetinib 45 mg, a kinase inhibitor used in melanoma and NSCLC, and in doing so has secured a shot at the largest single-product opportunity it has seen this year. The drug targets a $259 million US market. Alembic is the sole first applicant with a Paragraph IV certification, which means once final approval comes, it will have 180 days of generic exclusivity. That is a rare moat. For context, $259 million (~₹2,150 cr) is about 29% of Alembic's annual revenue, far above the materiality threshold. The company now has 242 cumulative ANDAs, but this one stands apart. The next test: when final approval lands and whether Alembic can launch quickly to capture the exclusivity window.
Questions answered
- What is Binimetinib used for?
- Binimetinib is a kinase inhibitor approved in combination with encorafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations and metastatic NSCLC with BRAF V600E mutation.
- How large is the US market for this drug?
- The estimated US market for generic Binimetinib 45 mg is $259 million for the twelve months ending March 2026, or about ₹2,150 crores.
- What does the 180-day exclusivity mean for Alembic?
- As the sole first applicant with a Paragraph IV certification, Alembic will have 180 days of generic marketing exclusivity once final approval is granted, meaning no other generic can compete during that period.
- How significant is this for Alembic financially?
- The market size of ~₹2,150 crores represents about 29% of Alembic's annual revenue of ₹7,345 crores, far exceeding the 7% materiality threshold. If Alembic captures a meaningful share, it could materially boost earnings.
- When will Alembic receive final approval?
- Tentative approval does not have a fixed timeline for final approval. It depends on the outcome of patent litigation, regulatory reviews, and potential settlement agreements. No schedule has been disclosed.
- How many US ANDA approvals does Alembic now have?
- Alembic now holds 242 cumulative ANDA approvals from the USFDA, comprising 222 final approvals and 20 tentative approvals.
Alembic Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on APLLTD →- 19 Jun 2026 · 1:50 PM IST Alembic eyes $259M cancer market with tentative US nod for Binimetinib
- 7d ago Alembic gets USFDA nod for generic Retin-A — but market is small
- 8d ago Alembic lands 180-day exclusivity shot on $91m US cancer drug
- 13d ago Alembic takes 45% in new Canadian pharma JV with Difgen Holdings
- 14d ago Alembic lands generic Haldol approval, but the US market is tiny